Cellosaurus logo
expasy logo

Cellosaurus MKN28 (CVCL_1416)

[Text version]
Cell line name MKN28
Synonyms MKN-28; MKN 28
Accession CVCL_1416
Resource Identification Initiative To cite this cell line use: MKN28 (RRID:CVCL_1416)
Comments Problematic cell line: Contaminated. Shown to be a MKN74 derivative (PubMed=20143388).
Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: COSMIC cell lines project.
Part of: JFCR39 cancer cell line panel.
Part of: JFCR45 cancer cell line panel.
Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00328.
Population: Japanese.
Doubling time: 28-32 hours (PubMed=3962675); 28 hours (PubMed=29435981); 30-34 hours (CelloPub=CLPUB00584).
Microsatellite instability: Stable (MSS) (PubMed=23671654; Sanger).
Omics: CRISPR phenotypic screen.
Omics: Deep exome analysis.
Omics: Deep quantitative proteome analysis.
Omics: DNA methylation analysis.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Omics: Transcriptome analysis by RNAseq.
Derived from site: Metastatic; Liver; UBERON=UBERON_0002107.
Sequence variations
HLA typing Source: PubMed=9023415
Class I

Source: PubMed=25960936
Class I
Class II
Genome ancestry Source: PubMed=30894373

Origin% genome
Native American0
East Asian, North83.28
East Asian, South16.71
South Asian0
European, North0
European, South0
Disease Gastric tubular adenocarcinoma (NCIt: C5473)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_2791 (MKN74)
Sex of cell Male
Age at sampling 37Y
Category Cancer cell line
STR profile Source(s): Cosmic-CLP; JCRB; KCLB; RCB


Run an STR similarity search on this cell line
Web pages https://cellbank.nibiohn.go.jp/legacy/cellbank/qualitycontrol/identification/summary.htm

Hojo H.
Establishment of cultured cell lines of human stomach cancer origin and their morphological characteristics.
Niigata Igakkai Zasshi 91:737-763(1977)

Motoyama T., Hojo H., Suzuki T., Oboshi S.
Evaluation of the regrowth assay method as an in vitro drug sensitivity test and its application to cultured human gastric cancer cell lines.
Acta Med. Biol. 27:49-63(1979)

PubMed=758928; DOI=10.1038/bjc.1979.3
Kinjo M., Oka K., Naito S., Kohga S., Tanaka K., Oboshi S., Hayata Y., Yasumoto K.
Thromboplastic and fibrinolytic activities of cultured human cancer cell lines.
Br. J. Cancer 39:15-23(1979)

PubMed=6862145; DOI=10.20772/cancersci1959.74.2_240
Naito S., Inoue S., Kinjo M., Tanaka K.
Thromboplastic and fibrinolytic activities of cultured human gastric cancer cell lines.
Gann 74:240-247(1983)

PubMed=3986962; DOI=10.1093/carcin/6.4.549
Watatani M., Ikenaga M., Hatanaka T., Kinuta M., Takai S.-i., Mori T., Kondo S.
Analysis of N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)-induced DNA damage in tumor cell strains from Japanese patients and demonstration of MNNG hypersensitivity of Mer xenografts in athymic nude mice.
Carcinogenesis 6:549-553(1985)

PubMed=3962675; DOI=10.1111/j.1440-1827.1986.tb01461.x
Motoyama T., Hojo H., Watanabe H.
Comparison of seven cell lines derived from human gastric carcinomas.
Acta Pathol. Jpn. 36:65-83(1986)

Yamada Y., Yoshida T., Hayashi K., Sekiya T., Yokota J., Hirohashi S., Nakatani K., Nakano H., Sugimura T., Terada M.
p53 gene mutations in gastric cancer metastases and in gastric cancer cell lines derived from metastases.
Cancer Res. 51:5800-5805(1991)

PubMed=1370612; DOI=10.1016/S0006-291X(05)80133-0
Matozaki T., Sakamoto C., Matsuda K., Suzuki T., Konda Y., Nakano O., Wada K., Uchida T., Nishisaki H., Nagao M., Kasuga M.
Missense mutations and a deletion of the p53 gene in human gastric cancer.
Biochem. Biophys. Res. Commun. 182:215-223(1992)

Sekiguchi M., Suzuki T.
Gastric tumor cell lines.
(In) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.287-316; Academic Press; New York (1994)

PubMed=9023415; DOI=10.1006/cimm.1996.1062
Seki N., Hoshino T., Kikuchi M., Hayashi A., Itoh K.
HLA-A locus-restricted and tumor-specific CTLs in tumor-infiltrating lymphocytes of patients with non-small cell lung cancer.
Cell. Immunol. 175:101-110(1997)

PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D
Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T., Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M., Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.
Screening the p53 status of human cell lines using a yeast functional assay.
Mol. Carcinog. 19:243-253(1997)

PubMed=11107048; DOI=10.1046/j.1440-1827.2000.01117.x
Yokozaki H.
Molecular characteristics of eight gastric cancer cell lines established in Japan.
Pathol. Int. 50:767-777(2000)

PubMed=11314020; DOI=10.1038/sj.onc.1204160
Kataoka H., Miura Y., Joh T., Seno K., Tada T., Tamaoki T., Nakabayashi H., Kawaguchi M., Asai K., Kato T., Itoh M.
Alpha-fetoprotein producing gastric cancer lacks transcription factor ATBF1.
Oncogene 20:869-873(2001)

PubMed=15723654; DOI=10.1111/j.1349-7006.2005.00016.x
Takada H., Imoto I., Tsuda H., Sonoda I., Ichikura T., Mochizuki H., Okanoue T., Inazawa J.
Screening of DNA copy-number aberrations in gastric cancer cell lines by array-based comparative genomic hybridization.
Cancer Sci. 96:100-110(2005)

PubMed=15767549; DOI=10.1158/1535-7163.MCT-04-0234
Nakatsu N., Yoshida Y., Yamazaki K., Nakamura T., Dan S., Fukui Y., Yamori T.
Chemosensitivity profile of cancer cell lines and identification of genes determining chemosensitivity by an integrated bioinformatical approach using cDNA arrays.
Mol. Cancer Ther. 4:399-412(2005)

PubMed=15900046; DOI=10.1093/jnci/dji133
Mashima T., Oh-hara T., Sato S., Mochizuki M., Sugimoto Y., Yamazaki K., Hamada J.-i., Tada M., Moriuchi T., Ishikawa Y., Kato Y., Tomoda H., Yamori T., Tsuruo T.
p53-defective tumors with a functional apoptosome-mediated pathway: a new therapeutic target.
J. Natl. Cancer Inst. 97:765-777(2005)

PubMed=15901131; DOI=10.1016/j.prp.2005.01.002
Murai Y., Hayashi S., Takahashi H., Tsuneyama K., Takano Y.
Correlation between DNA alterations and p53 and p16 protein expression in cancer cell lines.
Pathol. Res. Pract. 201:109-115(2005)

PubMed=20143388; DOI=10.1002/ijc.25242
Capes-Davis A., Theodosopoulos G., Atkin I., Drexler H.G., Kohara A., MacLeod R.A.F., Masters J.R.W., Nakamura Y., Reid Y.A., Reddel R.R., Freshney R.I.
Check your cultures! A list of cross-contaminated or misidentified cell lines.
Int. J. Cancer 127:1-8(2010)

PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=22336246; DOI=10.1016/j.bmc.2012.01.017
Kong D.-X., Yamori T.
JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.
Bioorg. Med. Chem. 20:1947-1951(2012)

PubMed=22490663; DOI=10.1016/j.bbrc.2012.03.122
Saiki Y., Yoshino Y., Fujimura H., Manabe T., Kudo Y., Shimada M., Mano N., Nakano T., Lee Y., Shimizu S., Oba S., Fujiwara S., Shimizu H., Chen N., Nezhad Z.K., Jin G., Fukushige S., Sunamura M., Ishida M., Motoi F., Egawa S., Unno M., Horii A.
DCK is frequently inactivated in acquired gemcitabine-resistant human cancer cells.
Biochem. Biophys. Res. Commun. 421:98-104(2012)

PubMed=23671654; DOI=10.1371/journal.pone.0063056
Lu Y.-H., Soong T.D., Elemento O.
A novel approach for characterizing microsatellite instability in cancer cells.
PLoS ONE 8:E63056-E63056(2013)

PubMed=25960936; DOI=10.4161/21624011.2014.954893
Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.
A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.
OncoImmunology 3:e954893.1-e954893.12(2014)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=29435981; DOI=10.1002/ijc.31304
Kim H.J., Kang S.K., Kwon W.S., Kim T.S., Jeong I., Jeung H.-C., Kragh M., Horak I.D., Chung H.C., Rha S.Y.
Forty-nine gastric cancer cell lines with integrative genomic profiling for development of c-MET inhibitor.
Int. J. Cancer 143:151-159(2018)

PubMed=29717028; DOI=10.1042/BSR20180277
Zhang Y.-Q., Yu S.-T., Zhang Z.-Z., Zhao G., Xu J.
Long non-coding RNA AK096174 promotes cell proliferation and invasion in gastric cancer by regulating WDR66 expression.
Biosci. Rep. 38:BSR20180277.1-BSR20180277.12(2018)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=30971826; DOI=10.1038/s41586-019-1103-9
Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M., Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R., Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P., van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L., Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.
Nature 568:511-516(2019)

PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)

Cell line collections (Providers) JCRB; JCRB0253
JCRB; NIHS0324 - Discontinued
JCRB; NIHS0325 - Discontinued
JCRB; FDSC0011 - Discontinued
KCLB; 80102
RCB; RCB1000 - Discontinued
Cell line databases/resources CLO; CLO_0037142
cancercelllines; CVCL_1416
Cell_Model_Passport; SIDM00260
CGH-DB; 119-1
CGH-DB; 9021-4
Cosmic-CLP; 908139
DepMap; ACH-002161
Anatomy/cell type resources BTO; BTO:0002381
Biological sample resources BioSample; SAMN03151847
CRISP screens repositories BioGRID_ORCS_Cell_line; 944
Chemistry resources ChEMBL-Cells; CHEMBL3307602
ChEMBL-Targets; CHEMBL614353
GDSC; 908139
PharmacoDB; MKN28_937_2019
PubChem_Cell_line; CVCL_1416
Encyclopedic resources Wikidata; Q54905823
Experimental variables resources EFO; EFO_0002831
Gene expression databases ArrayExpress; E-MTAB-783
ArrayExpress; E-MTAB-3610
GEO; GSM562396
GEO; GSM1670112
Polymorphism and mutation databases Cosmic; 801338
Cosmic; 848146
Cosmic; 848371
Cosmic; 873710
Cosmic; 875905
Cosmic; 877041
Cosmic; 887249
Cosmic; 888826
Cosmic; 897534
Cosmic; 908139
Cosmic; 918496
Cosmic; 922694
Cosmic; 926113
Cosmic; 968348
Cosmic; 983726
Cosmic; 1066230
Cosmic; 1067208
Cosmic; 1090460
Cosmic; 1093298
Cosmic; 1223588
Cosmic; 1436025
Cosmic; 1460710
Cosmic; 1482081
Cosmic; 1627264
Cosmic; 1995509
Cosmic; 2036660
Cosmic; 2069778
Cosmic; 2823226
IARC_TP53; 972
IARC_TP53; 21505
Progenetix; CVCL_1416
Proteomic databases PRIDE; PXD030304
Sequence databases EGA; EGAS00001000978
Entry history
Entry creation04-Apr-2012
Last entry update30-Jan-2024
Version number42